Zepzelca Fails Phase 3 Lung Cancer Trial, Limiting Jazz Pharma's Market Expansion
JAZZ has more than doubled off its 52-week low of $105.
Summary
Jazz Pharmaceuticals' drug Zepzelca (lurbinectedin) failed to meet its primary endpoint of overall survival in the Phase 3 Lagoon trial for second-line small cell lung cancer. This clinical setback limits the drug's potential market expansion and future revenue growth in a key oncology indication. The company confirmed that Zepzelca's existing first-line maintenance treatment approval remains unaffected. Jazz Pharma will now discuss next steps with the FDA regarding post-marketing requirements for the second-line indication.
At the time of this announcement, JAZZ was trading at $235.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.8B. The 52-week trading range was $105.00 to $243.32. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.